Background: Anti-programmed cell death protein 1 (PD-1) has been successfully used in carcinomas treatment. However, it causes significant adverse effects (AEs), including cutaneous reactions, particularly the life-threatening severe bullous skin reactions (SBSR) and toxic epidermal necrolysis (TEN).Case summary: Herein, we described for the first time a case report of SBSR induced by anti-PD-1 therapy in a cervical cancer patient. In addition, we revised existing literature on anti-PD-1 induced cutaneous reactions. We reported a cervical cancer patient who was treated with four successive cycles of Sintilimab and Toripalimab injections and developed systemic rashes, bullae, and epidermal desquamation, which worsened and led to infection, eventually causing death after being unresponsive to aggressive treatments.Conclusion: Anti-PD-1 antibodies commonly cause skin toxicity effects, some of which may be deadly. Therefore, healthcare providers should observe early symptoms and administer proper treatment to prevent aggravation of symptoms.
Purpose To explore the influence of different treatment schemes on the survival time of dying cancer patients and the characteristics of patients' death time. Method Group A: patients went to the Intensive care unit (ICU) for further treatment and were given mechanical assistance and other rescue measures; Group B: patients accepted drug rescue treatment in the general ward, and CPR was given in case of cardiac arrest. Group C: patients accepted only drug rescue treatment; Group D: No rescue treatment. We calculated the survival time of patients in different groups. We used circular statistics to analyze whether there was a significant trend in the month of death. Results The total survival time of group A was 138.0h. (95% confidence interval [CI], 109.1 to 166.8) versus group B 54.5h (95% [CI], 42.8 to 66.3) versus group C 60.0h (95% [CI], 51.7 to 68.3) versus group D 60.4 (95% [CI], 53.9 to 66.8). There was significant statistical significance between groups A vs. groups B, C, and D (P < .05), and there was no statistical difference between groups B, C, and D (P > .05). The deaths occurred in October of each year. Conclusions Medicated rescue therapy and CPR are ineffective for patients with endangered cancer, ICU treatment can prolong the survival time of dying patients. More cancer patients die in October.
The diagnosis and treatment of cancer of unknown primary site (CUP) present with difficulties and produce a poor prognosis. The current study presents the case of a patient with CUP in the mandibular region was treated with docetaxel and lobaplatin chemotherapy, and vascular embolization of the tumor. The tumor size was markedly reduced and the patient's quality of life improved following radiotherapy. The present case report is accompanied by a discussion of the literature to contextualize the treatment regimen for patients with CUP. These findings will support current treatment practices, inform oncologists and benefit patients with cancer.
Diagnosis and treatment of cancer of unknown primary (CUP)site present difficulties and produce a poor prognosis. The current case of CUP in the mandibular region was treated with docetaxel and lobaplatin chemotherapy and vascular embolization of the tumor. Tumor size was significantly reduced and the patient’s quality of life improved following radiotherapy. The case study is accompanied by a literature review to contextualize the treatment experience for CUP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.